10.24.19
West Pharmaceutical Services
3Q Revenues: $456.1 million (+6%)
3Q Earnings: $56.3 million (+2%)
YTD Revenues: $1.4 billion (+6%)
YTD Earnings: $177.8 million (+15%)
Comments: Proprietary Products Segment sales grew 6% to $345.2 million. Biologics market unit sales growth was led by NovaPure, Daikyo and Flurotec components as well as products incorporating Daikyo's Crystal Zenith technology. Generics market unit sales growth was led by sales of Daikyo components, products incorporating Crystal Zenith technology, self-injection platforms and Westar RU. Pharma market declines were due to the impact of a previously reported voluntary recall of our Vial2Bag product. Contract-Manufactured Products Segment sales grew 4% to $111.1 million led by sales of healthcare-related injection and diagnostic devices.
3Q Revenues: $456.1 million (+6%)
3Q Earnings: $56.3 million (+2%)
YTD Revenues: $1.4 billion (+6%)
YTD Earnings: $177.8 million (+15%)
Comments: Proprietary Products Segment sales grew 6% to $345.2 million. Biologics market unit sales growth was led by NovaPure, Daikyo and Flurotec components as well as products incorporating Daikyo's Crystal Zenith technology. Generics market unit sales growth was led by sales of Daikyo components, products incorporating Crystal Zenith technology, self-injection platforms and Westar RU. Pharma market declines were due to the impact of a previously reported voluntary recall of our Vial2Bag product. Contract-Manufactured Products Segment sales grew 4% to $111.1 million led by sales of healthcare-related injection and diagnostic devices.